Lyndon B. Johnson General Hospital First To Use PICO* Single Use Negative Pressure Wound Therapy System From Smith & Nephew

With its palm sized, one-button pump and revolutionary dressing technology that manages fluids without a bulky canister, the PICO system represents an entirely new way to deliver NPWT and a significant advancement for the patient, clinician and payer: It brings NPWT to a wider range of patients.  Its simplicity and ease of use enables more clinicians to use NPWT in a cost-effective manner.  For the payer, the PICO system is more affordable and can significantly reduce therapy costs associated with traditional NPWT as it is available off-the-shelf, helping to conserve and manage healthcare resources.

"LBJ Hospital aims to provide the highest quality care within tight economic limits," said Thomas Dugan, President, Smith & Nephew Advanced Wound Management, North America. "Smith & Nephew is committed to innovation that reduces the human and economic costs of wounds.  Reflecting this commitment, we built our PICO system to help clinicians make NPWT available to a broader range of patients at a lower cost. We are delighted to have supported Dr. Ahmed and LBJ Hospital in this way and we are excited by the rapid and enthusiastic adoption we are seeing in hospitals across the U.S."

Participating clinicians can see the PICO system in the Smith & Nephew Booth #4947 at AAOS 2012 in San Francisco, from February 7--11, 2012. More information is available at the PICO system's mobile compatible website, www.possiblewithpico.com.  Please follow @woundcare on Twitter for the latest news from the Advanced Wound Management division of Smith & Nephew.  Clinicians and patients may also refer to the 24/7 negative pressure wound therapy hotline, 866-998-NPWT (6798), for more information about the NPWT portfolio of products from Smith & Nephew.

About Smith & NephewSmith & Nephew is a global medical technology business dedicated to helping improve people's lives.  With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine, Trauma and Clinical Therapies, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-Looking StatementsThis document may contain forward-looking statements that may or may not prove accurate.  For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements.  Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature.  Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

« First ‹ Previous 1 2 3 Next › Last »